Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

The exploration of natural products and their structural analogues in neuropsychiatry has historically been a fertile area of research, driven by the ...

NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it has received approval for its Phase 2 clinical trial from the European ...

Brain implants, made from small clusters of brain cells, could help restore neural pathways damaged by Parkinson’s disease.

Consequently, speech can be a crucial modality in the initial phase of Parkinson’s disease prediction. In literature, diverse Machine Learning models are employed for Parkinson’s disease diagnosis ...

Brain implants that could help repair the pathways damaged by Parkinson’s disease are being developed by University of ...

Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...

Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...

Abstract: Parkinson’s disease (PD) is a chronic neurological disorder that ... Meanwhile, concerning the latter, large models that introduce complex and difficult-to-understand architectures reduce ...

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad 382355, Gujarat, India Department of Pharmacology and Toxicology, College of ...